The EU took the Anglo-Sweden company to court in April after the covid Vaccine manufacturer said it would deliver its 100-million-vaccine vaccine doses by the end of June, which it failed to do.
A European Union lawyer accused AstraZeneca on Wednesday of failing to honor his contract with the 27-nation Covid-19 drug company and asked a Belgian court to fine a large company.
The EU took the Anglo-Sweden company to court in April after the drug manufacturer said it would aim to deliver its 100-million-vaccine vaccine by the end of June, instead of the 300 million that had been identified in the trade agreement.
Brussels wants the company to deliver at least 120 million drugs by the end of June. AstraZeneca had already distributed 50 million doses in early May, a quarter of the 200 million vaccines identified in the agreement at the time.
"AstraZeneca did not even try to honor the contract," EU spokesman Rafael Jafferali told a Brussels court during the first hearing of the legal case.
He said the EU demanded 10 euros ($ 12.2) per day for each volume delay as compensation for non-compliance with EU contract. This sentence will be effective from July 1, 2021, if the judge accepts it.
The EU spokesman said the EU wanted an additional fine of at least 10 million euros for violating any agreement a judge could make.
A decision is expected next month.
"This is not a contract for the supply of shoes or T-shirts," AstraZeneca lawyer Hakim Boularbah told the court on Wednesday, stressing the difficulty of making a new product.
The company has reiterated that the contract was not binding as it was committed to making "the best efforts" to deliver volumes. AstraZeneca's lawyer told the judge that the vaccine had been sold at a cost.
Jafferali said the system was not respected because the drug manufacturer had not yet reached the organization with 50 million doses manufactured in listed companies as EU suppliers, of which 39 million were made in Britain, 10 million in the United States and one million in the Netherlands.
The attorney said the ratings were "transferred" to other clients.
The company said British production prices were reserved under a British government contract signed with the University of Oxford, which created the policy.
Jafferali said AstraZeneca had promised the EU contract not to have any other issues that would prevent it from complying with the terms of the agreement.
The lawyer also claimed that AstraZeneca had failed to contact the EU in a timely manner due to the magnitude of its supply problems because it had repeatedly sent messages, including public ones, that it was able to achieve its goals, before finally admitting serious mistakes in March.
The company had warned the EU in December of production problems, but only contacted at the end of January, just before the start of delivery, a much larger cut than expected in the first quarter.
A European Union lawyer accused AstraZeneca on Wednesday of failing to honor his contract with the 27-nation Covid-19 drug company and asked a Belgian court to fine a large company.
The EU took the Anglo-Sweden company to court in April after the drug manufacturer said it would aim to deliver its 100-million-vaccine vaccine by the end of June, instead of the 300 million that had been identified in the trade agreement.
Brussels wants the company to deliver at least 120 million drugs by the end of June. AstraZeneca had already distributed 50 million doses in early May, a quarter of the 200 million vaccines identified in the agreement at the time.
"AstraZeneca did not even try to honor the contract," EU spokesman Rafael Jafferali told a Brussels court during the first hearing of the legal case.
He said the EU demanded 10 euros ($ 12.2) per day for each volume delay as compensation for non-compliance with EU contract. This sentence will be effective from July 1, 2021, if the judge accepts it.
The EU spokesman said the EU wanted an additional fine of at least 10 million euros for violating any agreement a judge could make.
A decision is expected next month.
"This is not a contract for the supply of shoes or T-shirts," AstraZeneca lawyer Hakim Boularbah told the court on Wednesday, stressing the difficulty of making a new product.
The company has reiterated that the contract was not binding as it was committed to making "the best efforts" to deliver volumes. AstraZeneca's lawyer told the judge that the vaccine had been sold at a cost.
Jafferali said the system was not respected because the drug manufacturer had not yet reached the organization with 50 million doses manufactured in listed companies as EU suppliers, of which 39 million were made in Britain, 10 million in the United States and one million in the Netherlands.
The attorney said the ratings were "transferred" to other clients.
The company said British production prices were reserved under a British government contract signed with the University of Oxford, which created the policy.
Jafferali said AstraZeneca had promised the EU contract not to have any other issues that would prevent it from complying with the terms of the agreement.
The lawyer also claimed that AstraZeneca had failed to contact the EU in a timely manner due to the magnitude of its supply problems because it had repeatedly sent messages, including public ones, that it was able to achieve its goals, before finally admitting serious mistakes in March.
The company had warned the EU in December of production problems, but only contacted at the end of January, just before the start of delivery, a much larger cut than expected in the first quarter.
Posts
